Biomea Fusion Presents Achievement of Minimal Residual Disease Negativity (MRD-neg) in First Complete Responder from Ongoing Phase I Study (COVALENT-101) of BMF-219 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) at the 2023 ASH Annual Meeting
December 11, 2023 09:25 ET
|
Biomea Fusion, Inc.
BMF-219 demonstrated early signs of clinical activity and ability to achieve durable and sustained complete responses (CRs) with minimal residual disease negativity (MRD-neg) in acute myeloid leukemia...
Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts
December 09, 2023 17:30 ET
|
Biomea Fusion, Inc.
At Week 26, 22 weeks after the last dose of BMF-219, the 200 mg cohorts increased the percentage of patients to approximately 40% with durable HbA1c reduction of 1% or more as compared to the 100 mg...
Biomea Fusion Presents Long-Term Follow-Up Data Showing Improved Glycemic Control after 22 Weeks Off Treatment in Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes in a Poster Presentation at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
December 08, 2023 09:00 ET
|
Biomea Fusion, Inc.
BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes At Week 26, 22 weeks after the last dose of BMF-219,...
Biomea Fusion to Present Long-Term Follow-Up Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes and Results from Ex-Vivo Human Islet Experiments at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
December 07, 2023 09:15 ET
|
Biomea Fusion, Inc.
BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes In a poster presentation on Thursday, Dec. 7th at...
Biomea Fusion Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 Diabetes
December 05, 2023 08:30 ET
|
Biomea Fusion, Inc.
BMF-219 is a novel investigational covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes Health Canada has cleared the initiation of...
Biomea Fusion Announces Acceptance of Three Abstracts for its Novel Menin Inhibitor Highlighting Durable Glycemic Control in Diabetes Patients at the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in 2024
November 27, 2023 08:30 ET
|
Biomea Fusion, Inc.
New clinical data from all dosing cohorts (n=62) initiated to date from the escalation portion of COVALENT-111 and long-term (26 weeks) follow-up data of the 200 mg dosed cohorts will be featured...
Biomea Fusion Abstract “BMF-219: A Novel Therapeutic Agent to Reestablish Functional Beta Cells and Provide Long-term Glycemic Control" Selected as One of Six Oral Presentations at 21st World Congress Insulin Resistance, Diabetes & Cardiovascular Disease
November 16, 2023 08:30 ET
|
Biomea Fusion, Inc.
New clinical data providing long-term 26 weeks follow-up of the initial two dosing cohorts of COVALENT-111 will be presented during the Abstract Oral Presentation Session at WCIRDC meeting on Friday,...
Biomea Fusion to Present New Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
November 08, 2023 16:05 ET
|
Biomea Fusion, Inc.
An abstract, “BMF-219: A novel therapeutic agent to reestablish functional beta cells and provide long-term glycemic control” will be presented during the WCIRDC meeting held in Los Angeles, December...
Biomea Fusion Announces Two Poster Presentations at Upcoming ASH Annual Meeting 2023
November 02, 2023 09:05 ET
|
Biomea Fusion, Inc.
First presentation of clinical data from ongoing COVALENT-101 trial of covalent menin inhibitor BMF-219 as a treatment for patients with liquid tumorsTrial in progress presentation featuring study...
Biomea Fusion Reports Third Quarter 2023 Financial Results and Corporate Highlights
October 30, 2023 16:01 ET
|
Biomea Fusion, Inc.
Demonstrated durable HbA1c lowering in the escalation portion of ongoing Phase II study in type 2 diabetes (COVALENT-111), with 84% of all patients showing a reduction of HbA1c after 4 weeks dosing...